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Cardiac hypertrophy is associated with profound remodeling of Ca2+ signal-
ing pathways. During the early, compen-
sated stages of hypertrophy, Ca2+ fluxes 
may be enhanced to facilitate greater 
contraction, whereas as the hypertrophic 
heart decompensates, Ca2+ homeostatic 
mechanisms are dysregulated leading 
to decreased contractility, arrhythmia 
and death. Although ryanodine recep-
tor Ca2+ release channels (RyR) on the 
sarcoplasmic reticulum (SR) intracellu-
lar Ca2+ store are primarily responsible 
for the Ca2+ flux that induces myocyte 
contraction, a role for Ca2+ release via 
the inositol 1,4,5-trisphosphate recep-
tor (InsP
3
R) in cardiac physiology has 
also emerged. Specifically, InsP
3
-induced 
Ca2+ signals generated following myocyte 
stimulation with an InsP
3
-generating 
agonist (e.g., endothelin, ET-1), lead to 
modulation of Ca2+ signals associated 
with excitation-contraction coupling 
(ECC) and the induction of spontane-
ous Ca2+ release events that cause cellular 
arrhythmia. Using myocytes from spon-
taneously hypertensive rats (SHR), we 
recently reported that expression of the 
type 2 InsP
3
R (InsP
3
R2) is significantly 
increased during hypertrophy. Notably, 
this increased expression was restricted 
to the junctional SR in close proximity to 
RyRs. There, enhanced Ca2+ release via 
InsP
3
Rs serves to sensitize neighboring 
RyRs causing an augmentation of Ca2+ 
fluxes during ECC as well as an increase 
in non-triggered Ca2+ release events. 
Although the sensitization of RyRs may 
be a beneficial consequence of elevated 
InsP
3
R expression during hypertrophy, 
the spontaneous Ca2+ release events 
are potentially of pathological signifi-
cance giving rise to cardiac arrhythmia. 
InsP
3
R2 expression was also increased in 
hypertrophic hearts from patients with 
ischemic dilated cardiomyopathy and 
aortically-banded mice demonstrating 
that increased InsP
3
R expression may 
be a general phenomenon that underlies 
Ca2+ changes during hypertrophy.
To meet increased haemodynamic require-
ments, or as a result of damage, the heart 
elicits a hypertrophic response. This 
response is characterized by an enlarge-
ment of the cardiac muscle mass due to 
increased cell size rather than cell num-
ber.1,2 Hypertrophy results from both 
physiological (pregnancy, exercise) and 
pathological stimuli (hypertension, isch-
emic heart disease) and can initially be 
a beneficial adaptive response. However, 
persistent cardiac stress may lead to a dec-
ompensated form of hypertrophy, which 
can lead to arrhythmia and ultimately 
heart failure and death. Indeed, cardiac 
hypertrophy is a predictor of future heart 
failure and death.2,3 These pathologies are 
of major clinical significance and together 
with other cardiovascular diseases are now 
the primary cause of death in the devel-
oped world.4
Ca2+ is key to cardiac function—
stimulating myocyte contraction via 
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Although amplification of Ca2+ cycling 
is considered as a general mechanism for 
increasing cardiac output during hyper-
trophy, myocytes isolated from certain 
hypertrophy models exhibit either no 
change, or even suppression, in their 
ECC-mediated Ca2+ fluxes.27,28 As such, 
the mechanisms underlying remodeling of 
Ca2+ cycling during hypertrophy are not 
fully understood. In hypertrophic failing 
myocytes, Ca2+ cycling is suppressed caus-
ing decreased contractility. In this condi-
tion, defects in coupling between L-type 
channels and RyRs due to a breakdown 
in the t-tubular network,27 decreases in 
SERCA-mediated Ca2+ sequestration into 
the SR lumen,29 and increased Ca2+ leak 
from the SR via hyper-phosphorylated 
RyRs30 have all been shown to be involved 
in pathology.
The reason for this array of Ca2+ signal-
ing phenotypes during hypertrophy may 
lie in the panoply of hypertrophy models 
employed. For example, hypertrophy is 
induced by haemodynamic loading (such 
as aortic banding), interruption of myocar-
dial blood supply (infarction) and interfer-
ing of heart rate (pacing or AV block).23,31 
More recently, genetic models of hypertro-
phy have also been employed.32 Even more 
variability between studies is introduced 
by the hypertrophic stage at which Ca2+ 
signaling measurements are made and the 
location of the myocardium from which 
myocytes are isolated.23 The SHR model 
offers considerable advantages. The tempo-
ral development of hypertrophy in SHRs 
has been well characterized and develops 
slowly between the age of 2 and 6 months 
subsequent to the onset of systemic hyper-
tension.33 After the development of hyper-
trophy, there is also a long latency before 
the development of heart failure at 20–24 
months.26 This contrasts with surgically-
induced models where hypertrophy devel-
ops 1–2 weeks post surgery.31 However, our 
results show that the increase in InsP
3
R 
expression seems to be independent of how 
hypertrophy has been induced.15
Considering the pro-arrhythmic effect 
of increased InsP
3
R expression, which is 
clearly evident in our study, this raises 
the question of why InsP
3
R expression 
is enhanced in hypertrophic and fail-
ing cardiomyocytes? During hypertro-
phy a decrease in the coupling efficiency 
arrhythmias associated with hypertrophy 
and heart failure.25 Whether altered InsP
3
R 
signaling also contributes to remodeling of 
Ca2+ homeostasis during cardiac hypertro-
phy is not yet determined.
In a recent study,15 we established that 
augmented expression and Ca2+ release 
through InsP
3
Rs contribute to enhanced 
Ca2+ fluxes and increased spontane-
ous arrhythmogenic Ca2+ events associ-
ated with hypertrophy. As a model to 
study hypertrophy-dependent changes 
in Ca2+ signaling, we used hypertrophic 
ventricular cardiomyocytes from spon-
taneously hypertensive rats (SHR) and 
non-hypertrophic ventricular cardiomyo-
cytes from Wistar Kyoto rats (WKY) as 
controls.26 We found that in hypertrophic 
myocytes InsP
3
R2 expression was spe-
cifically increased in the junctional SR 
membrane, thereby increasing the num-
bers of InsP
3
Rs in close proximity with 
type 2 RyRs (RyR2), the expression of 
which was unchanged as a result of hyper-
trophy. Enhanced Ca2+ release through 
these InsP
3
Rs sensitized their neighboring 
RyRs, thereby enhancing CICR leading to 
bigger Ca2+ transients and greater myocyte 
contraction. Moreover, the sensitization of 
RyR opening through increased InsP
3
-
induced Ca2+ release (IICR) resulted in 
a higher propensity for the generation of 
elementary Ca2+ release events and extra-
systolic Ca2+ transients, which could act 
as a substrate for cardiac arrhythmia in 
vivo. Interestingly, we could not only show 
that InsP
3
R2 expression was increased in 
hypertrophic rat cardiomyocytes but also 
in cardiomyocytes isolated from aorti-
cally-banded mice and in human hearts 
displaying ischemic dilated cardiomyopa-
thy. We showed by immunoblotting and, 
as presented here, by immunohistochem-
istry that InsP
3
R2 expression is increased 
in diseased human hearts compared to 
control hearts (Fig. 1). These micrographs 
also illustrate that InsP
3
R2 expression is 
restricted to myocytes and is not present 
in non-myocyte cells, for example sur-
rounding the vessels.
An increase in InsP
3
R2 expression 
therefore seems to be a general phenom-
enon occurring during cardiac disease. 
This is surprising considering the lack of 
consensus regarding the different effects 
of hypertrophy on Ca2+ signaling.23 
 excitation-contraction coupling (ECC)5 
and controlling the transcription of genes 
that underlies the induction of hyper-
trophy.6,7 ECC is initiated by an action 
potential (AP) originating at the sino-
atrial node. Coordinated conduction of 
this action potential through the heart 
results in a synchronized contraction of 
the heart chambers. The propagating 
action potential depolarizes the myo-
cyte plasma membrane thereby opening 
voltage-sensitive L-type Ca2+ channels 
and allowing Ca2+ to enter the cell. This 
‘trigger’ Ca2+, termed a sparklet,8 induces 
opening of ryanodine receptor (RyR) 
Ca2+ release channels on the juxtaposed 
sarcoplasmic reticulum (SR) intracel-
lular Ca2+ store—a process called Ca2+-
induced Ca2+ release (CICR).9 CICR 
causes a global elevation in Ca2+, which 
leads to myocyte contraction. Relaxation 
is then brought about by extrusion of 
Ca2+ across the sarcolemma by the Na+/
Ca2+ exchanger (NCX) and by its seques-
tration into the SR by the SERCA2 Ca2+ 
ATPase.
In addition to RyRs, cardiomyocytes 
also express inositol 1,4,5-triphosphate 
receptor Ca2+ release channels (InsP
3
Rs), 
albeit outnumbered by RyRs 50:1.10-12 
Since InsP
3
Rs have been discovered in the 
heart, it has been questioned how the rela-
tively small amount of Ca2+ that is released 
via InsP
3
 can have any physiological func-
tion in the midst of the large amount of 
Ca2+ that is cycled through RyRs during 
every heart beat. In mammals, there are 
three InsP
3
R isoforms (types 1, 2 and 3),13,14 
with type 2 being the main isoform in the 
heart.10,12 Ca2+ release through InsP
3
Rs 
has been shown to mediate inotropy and 
arrhythmogenic Ca2+ release events as well 
as contribute to the hypertrophic effect of 
G
q
-coupled agonists such as the vasoactive 
peptide endothelin-1 (ET-1).15-22
Profound remodeling of the Ca2+ sig-
naling apparatus has been reported to 
occur as a result of cardiac hypertrophy 
and failure.23 Whilst enhancement of Ca2+ 
transients facilitates greater myocyte con-
traction during adaptive hypertrophy, Ca2+ 
fluxes are diminished during heart failure 
resulting in decreased contractility and 
thus, cardiac output.24 Remodeling of the 
activity and function of the Ca2+ signal-
ing proteome also underlies the increased 
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hypertrophic phenotype. The subcellular 
localization of InsP
3
R2 expression could 
be mediated via interactions with acces-
sory proteins such as Ankyrin B, which has 
been shown to localize InsP
3
Rs.34 Whether 
the mechanisms that mediate a preferen-
tial increase in InsP
3
Rs in the junctional 
zones and not around the nucleus during 
hypertrophy play any role in restricting 
the recently described pro-hypertrophic 
action of InsP
3
-induced calcium release 
(IICR) in the nucleus also remains to be 
determined.16,35
A dramatic consequence of hypertro-
phy for Ca2+ signaling observed in our 
is achieved. Our data would suggest that 
InsP
3
R expression increases concomitant 
with or is a product of hypertrophy and 
is not causal. In support of this conclu-
sion, non-hypertrophic hearts from four 
month old SHRs do not exhibit increased 
InsP
3
R expression compared to WKY con-
trols.15 Moreover, hypertrophy is induced 
in vitro in an InsP
3
-dependent manner 
within 24 hours, a time period that would 
not allow for elevated InsP
3
R expression 
to have effect. Thus, it is likely that the 
role of increased InsP
3
Rs detected during 
hypertrophy is to modify calcium signals, 
and possibly to also act to sustain the 
between plasma membrane L-type chan-
nels and RyR channels due to an increase 
in the width of the dyadic cleft has been 
observed.28 This deficit in ECC did not 
significantly affect contractile function 
and was overcome by beta-adrenergic 
stimulation. Here, sensitization of RyR 
opening due to increased Ca2+ release 
through InsP
3
Rs could compensate for 
the lack of coupling efficiency, even under 
basal conditions.
What remains to be determined is 
how InsP
3
R2 expression during hyper-
trophy is regulated and how the striking 
junctional pattern of InsP
3
R2 expression 
Figure 1. expression of insP3r2 is increased in cardiomyocytes from human patients suffering from ischemic dilated cardiomyopathy. immunohis-
tochemical detection of insP3r2 (brown) in cardiomyocytes from control patients (a) and in cardiomyocytes from patients showing ischemic dilated 
cardiomyopathy (B). Higher magnification images for (A and B) are presented in (C and D) respectively. Control staining of hypertrophic myocytes 
without using insP3R2 primary antibody are presented at low and high magnification in (E and F) respectively. These data are representative of images 
taken from slides prepared from two control and two diseased hearts. Non-myocyte cells surrounding a blood vessel (indicated by the black arrow) do 
not stain for insP3r2. the size of the bar is indicated in each image. the nuclei are indicated in blue.
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susceptibility for arrhythmias, even under 
non-stressed conditions.
Our recent study15 presents a plausible 
mechanism why hypertrophic hearts are 
more prone to cardiac arrhythmia and 
proposes InsP
3
R2 as a possible target for 
the development of new drugs against 
hypertrophy-related arrhythmia.
Materials and Methods
Animal models. Male SHRs and normo-
tensive Wistar-Kyoto (WKY) rats were 
obtained from Harlan, UK, and were 
housed under control conditions with ad 
libitum food and water. All experiments 
were performed in accordance with the 
guidelines from the code of practice for 
humane killing under Schedule 1 of the 
Animals (Scientific Procedures) Act 1986.
Patients. Left ventricular tissue samples 
of human failing hearts were from indi-
viduals undergoing heart transplantation 
due to end-stage heart failure. All samples 
were obtained from male caucasians, aged 
41–62. Samples from non-failing donor 
hearts were provided by the “UK Human 
Tissue Bank”. After cardiectomy, left 
ventricular samples were frozen in liquid 
nitrogen and stored at -80°C. Detailed 
information about the patients is included 
in Harzheim et al. 2009. All experiments 
involving human tissue samples have been 
approved by the Cambridgeshire Research 
Ethics Committee.
I m m u n o h i s t o c h e m i s t r y . 
Immunohistochemistry was performed as 
previously described.41 Paraffin tissue sec-
tions were prepared from non-diseased 
human hearts and from hearts with isch-
emic dilated cardiomyopathy (tissue source 
described above). Sections were deparaf-
finized and antigen retrieved using basic cit-
rate buffer, after which slides were washed 
with PBS and blocked with 0.3% H
2
O
2
/PBS 
for 10 mins. After a further wash in PBS, 
slides were incubated with 5% BSA/PBS 
for 1 hour at room temp. Slides were then 
incubated overnight at 4°C with polyclonal 
rat anti InsP
3
R2 antibody15 diluted at 1:50 
in 5% BSA. After removal of excess primary 
antibody by washing in PBS, slides were 
incubated with HRP-conjugated secondary 
antibody diluted at 1:400 for 30 minutes 
at room temp. After washing, slides were 
incubated with ABC reagent for 30 mins at 
As well as being manifest as spontane-
ous Ca2+ release events and extra systolic 
Ca2+ transients, increased InsP
3
R expres-
sion resulted in a greater rise in diastolic 
[Ca2+] in hypertrophic myocytes fol-
lowing ET-1 or IICR stimulation.15 As a 
result, diastolic [Ca2+] was brought closer 
to the threshold for activation of RyRs, 
thereby increasing the incidence of sto-
chastic Ca2+ release events and accelerat-
ing the generation of pacing-evoked Ca2+ 
transients. These findings are consistent 
with data from InsP
3
R2-deficient atrial 
myocytes which exhibited a decrease in 
the ET-1-evoked elevation in diastolic 
[Ca2+].17
The arrhythmogenic effect of InsP
3
-
stimulated Ca2+ release events in the ven-
tricles is potentially more catastrophic 
than in the atria. Whereas atrial fibrilla-
tion only has potentially serious conse-
quences over the long term, ventricular 
fibrillation is potentially immediately life-
threatening. This situation is further exac-
erbated by increases in the expression of 
additional components of the pathway 
that leads to InsP
3
 generation. Specifically, 
levels of cardiac ET-1 and also that of 
its receptor (ET
A
R), are elevated during 
development of hypertension and hyper-
trophy (Fig. 2).38,39 Moreover, phospholi-
pase C beta1 levels have also been recently 
reported to be increased during atrial 
hypertrophy.40 Together, enhanced activ-
ity of this signaling pathway as a result of 
hypertrophy would promote greater Ca2+ 
release through InsP
3
Rs, and heighten the 
study was the increased occurrence of 
extra-systolic Ca2+ transients following 
ET-1 or InsP
3
 ester (cell permeant InsP
3
) 
application. The relatively low incidence 
of InsP
3
-stimulated Ca2+ release events in 
WKY myocytes is consistent with our pre-
vious work in Wistar rat ventricular myo-
cytes.10,20-22 The enhanced incidence of 
extra-systolic Ca2+ transients in hypertro-
phic ventricular myocytes is reminiscent 
of previous findings in atrial myocytes, 
which express ~6-fold more InsP
3
Rs 
under normal conditions.17,20,22,36 Due to 
their higher basal expression of InsP
3
Rs, 
stimulation of atrial myocytes with InsP
3
 
or InsP
3
-generating agonists, such as ET-1, 
potently induce extra-systolic Ca2+ release 
events.20 Although insignificant by them-
selves, these miniature Ca2+ release events 
can provide sufficient Ca2+ to catalyze fur-
ther Ca2+ release through CICR and cause 
AP-independent increases in [Ca2+]
i
 that 
could potentially result in arrhythmia.17 
This role of Ca2+ release through InsP
3
Rs 
has been substantiated in InsP
3
R2-
deficient mice, in which ET-1- and InsP
3
-
stimulated arrhythmias in atrial myocytes 
were completely abolished.17 Interestingly, 
InsP
3
Rs in atrial myocytes are located on 
the SR underlying the sarcolemma20—the 
functional equivalent of the junctional 
zone created by the juxtaposition of the SR 
terminal cisternae and the t-tubular mem-
brane in ventricular myocytes.37 Thus, 
in hypertrophic ventricular myocytes, 
ECC may mirror that observed in atrial 
myocytes.
Figure 2. expression of etar is increased in hypertrophic SHr hypertrophic myocytes. 25 μg of 
total cell lysate prepared from left ventricle taken from SHR and WKY hearts from 6 month old 
animals was subjected to immunoblot analysis following SdS-PaGe. analysis of samples prepared 
from 4 control (WKY) and 4 hypertrophic (SHR) hearts are shown. An immunoblot of α-actinin 
in the same samples is presented as loading control. We have previously established that myocytes 
from 6 month old SHrs are hypertrophic exhibiting increased size and expression of atrial natri-
uretic factor (anF).15
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Immunoblot detection of ET
A
R. 
Protein expression was detected as previ-
ously described.42 In brief, proteins were 
extracted from ventricular myocytes from 
WKY rats and SHRs in lysis buffer (10 
mM Tris-HCl, pH 7.6, 140 mM NaCl, 
1 mM EDTA, 1% Triton X-100, pro-
tease and phosphatase inhibitor cocktail 
(Sigma)). Protein extracts (25 μg) were 
then subjected to SDS-PAGE (10% Bis-
Tris NuPage, Invitrogen) and subsequent 
immunoblot analysis with antibodies 
directed against the ET
A
R (Alomone labs) 
and alpha-actinin (Sigma). Immune-
complexes were detected by enhanced 
chemiluminescence with anti-mouse or 
anti-rabbit IgG coupled to horseradish per-
oxidise as the secondary antibody (Jackson 
Immuno Research Laboratories).
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